{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:15Z","timestamp":1787010135767,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Goal:<\/jats:title>\n                    <jats:p>The objective of this study was to characterize an autoimmune hepatitis (AIH)\/nonalcoholic fatty liver disease (NAFLD) overlap cohort, determine if they received standard of care treatment, and delineate their outcomes in comparison with patients with AIH or NAFLD alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>AIH is a relatively rare and heterogeneously presenting liver disease of unknown etiology. NAFLD is a leading cause of liver disease worldwide. AIH treatment includes steroids, which have adverse metabolic effects that can worsen NAFLD. No treatment guidelines are available to mitigate this side on AIH\/NAFLD overlap patients. Few studies to date have examined these patients\u2019 characteristics, management practices, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A single-center, retrospective chart review study examining biopsy-proven AIH\/NAFLD, AIH, and NAFLD patients. Characteristics, treatment, and 1- and 3-year outcomes (all-cause mortality, need for liver transplantation, or decompensated cirrhosis) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 72 patients (36.1% AIH\/NAFLD, 34.7% AIH, and 29.2% NAFLD) were included. AIH\/NAFLD patients were found to be more often Hispanic\/Latino, female, and with lower liver aminotransaminases, immunoglobulin G, and anti\u2013smooth muscle antibody positivity. AIH\/NAFLD patients were less likely to receive standard of care treatment. No significant differences in outcomes were seen between AIH\/NAFLD and either AIH or NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our study demonstrated that AIH\/NAFLD patients have unique characteristics and are less likely to receive standard of care treatment compared with patients with AIH alone. Despite this, no difference in outcomes (all-cause mortality, need for liver transplantation, or decompensated cirrhosis) was seen. Given NAFLD\u2019s rising prevalence, AIH\/NAFLD cases will likely increase, and may benefit from alternative treatment guidelines to prevent worsening of NAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mcg.0000000000001817","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T16:40:52Z","timestamp":1675356052000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease"],"prefix":"10.1097","volume":"58","author":[{"given":"Jessica","family":"Strzepka","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center, Chicago, IL, Department of Internal Medicine, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center, Chicago, IL, Department of Internal Medicine, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan M.","family":"Ritz","sequence":"additional","affiliation":[{"name":"Bioinformatics and Biostatistics Core, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costica","family":"Aloman","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Rush University Medical Center, Chicago, IL; Department of Hepatology, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Reau","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Rush University Medical Center, Chicago, IL; Department of Hepatology, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12072-010-9183-5","article-title":"Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management","volume":"4","author":"Oo","year":"2010","journal-title":"Hepatol Int"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"430","DOI":"10.5009\/gnl19261","article-title":"Autoimmune hepatitis: 2019 update","volume":"14","author":"Tanaka","year":"2010","journal-title":"Gut Liver"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/0016-5085(93)91081-R","article-title":"Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis","volume":"105","author":"Czaja","year":"1993","journal-title":"Gastroenterology"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/hep.22513","article-title":"Performance parameters of the diagnostic scoring systems for autoimmune hepatitis","volume":"48","author":"Czaja","year":"2008","journal-title":"Hepatology"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-016-4213-3","article-title":"Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease","volume":"61","author":"De Luca-Johnson","year":"2016","journal-title":"Dig Dis Sci"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jgh3.12046","article-title":"Non-alcoholic fatty liver disease in patients with autoimmune hepatitis","volume":"2","author":"Takahashi","year":"2018","journal-title":"JGH Open"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/cld.710","article-title":"The epidemiology of nonalcoholic steatohepatitis","volume":"11","author":"Younossi","year":"2018","journal-title":"Clin Liver Dis"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease: NAFLD Disease Burden\u2014US, 2015-2030","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"367.e5","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R20-20250613","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/DMSO.S247379","article-title":"Glucocorticoid-induced fatty liver disease","volume":"13","author":"Rahimi","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: Autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"R22-20250613","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1016\/S0618-8278(19)30779-0","article-title":"FRI-029-Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: important player or innocent bystander?","volume":"70","author":"Zachou","year":"2019","journal-title":"J Hepatol"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.02.001","article-title":"NAFLD and autoimmune hepatitis: do not judge a book by its cover","volume":"75","author":"Dalekos","year":"2020","journal-title":"Eur J Intern Med"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2016.02.007","article-title":"Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model","volume":"69","author":"M\u00fcller","year":"2016","journal-title":"J Autoimmun"},{"key":"R25-20250613","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/hep4.1689","article-title":"Patient determinants for histologic diagnosis of NAFLD in the real world: a TARGET-NASH Study","volume":"5","author":"Barritt","year":"2021","journal-title":"Hepatol Commun"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000001817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T18:04:17Z","timestamp":1749837857000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000001817"}},"subtitle":["Characteristics, Treatment, and Outcomes"],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0000000000001817","relation":{},"ISSN":["1539-2031"],"issn-type":[{"value":"1539-2031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"2022-07-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}